Genome-wide integrated analyses of androgen receptor signaling in prostate cancer based on high-throughput technology

Current Drug Targets

Volumn 14, Issue 4, 2013, Pages 472-480

  Horie Inoue, Kuniko ^a   Inoue, Satoshi ^a,b  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Androgen receptor; Cap analysis gene expression; Chromatin immunoprecipitation; Prostate cancer

Indexed keywords

AMYLOID PRECURSOR PROTEIN; ANDROGEN RECEPTOR; COMPLEMENTARY DNA; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; HISTONE ACETYLTRANSFERASE; MICRORNA; PROTEIN KINASE C; RNA POLYMERASE II; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTOME; UNTRANSLATED RNA;

CANCER PROGNOSIS; CHROMATIN IMMUNOPRECIPITATION; CHROMOSOME 21; CHROMOSOME 22; DNA MICROARRAY; GENE EXPRESSION; GENE MAPPING; GENETIC ASSOCIATION; HIGH THROUGHPUT SCREENING; HISTONE ACETYLATION; HISTONE METHYLATION; HUMAN; MICROARRAY ANALYSIS; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TRANSCRIPTION INITIATION SITE;

ANIMALS; GENOME-WIDE ASSOCIATION STUDY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MALE; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 84876701211     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450111314040008     Document Type: Review

References (62)

1. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10: 33-9.
2. Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 2004; 351: 1488-90.
3. Bluemn EG, Nelson PS. The androgen/androgen receptor axis in prostate cancer. Curr Opin Oncol 2012; 24: 251-7.
4. Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear receptor superfamily: the second decade. Cell 1995; 83: 835-9.
5. Bennett NC, Gardiner RA, Hooper JD, Johnson DW, Gobe GC. Molecular cell biology of androgen receptor signalling. Int J Biochem Cell Biol 2010; 42: 813-27.
6. Nelson PS, Clegg N, Arnold H, et al. The program of androgenresponsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci USA 2002; 99: 11890-5.
7. Shaffer PL, Jivan A, Dollins DE, Claessens F, Gewirth DT. Structural basis of androgen receptor binding to selective androgen response elements. Proc Natl Acad Sci USA 2004; 101: 4758-63.
8. Horie-Inoue K, Takayama K, Bono HU, Ouchi Y, Okazaki Y, Inoue S. Identification of novel steroid target genes through the combination of bioinformatics and functional analysis of hormone response elements. Biochem Biophys Res Commun 2006; 339: 99-106.
9. Szmulewitz RZ, Chung E, Al-Ahmadie H, et al. Serum/ glucocorticoid-regulated kinase 1 expression in primary human prostate cancers. Prostate 2012; 7: 157-64.
10. Dehm SM, Tindall DJ. Molecular regulation of androgen action in prostate cancer. J Cell Biochem 2006; 99: 333-44.
11. Palazzolo I, Gliozzi A, Rusmini P, et al. The role of the polyglutamine tract in androgen receptor. J Steroid Biochem Mol Biol 2008; 108: 245-53.
12. Jerónimo C, Bastian PJ, Bjartell A, et al. Epigenetics in prostate cancer: biologic and clinical relevance. Eur Urol 2011; 60: 753-66.
13. Metzger E, Wissmann M, Yin N, et al. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 2005; 437: 436-9.
14. Metzger E, Yin N, Wissmann M, et al. Phosphorylation of histone H3 at threonine 11 establishes a novel chromatin mark for transcriptional regulation. Nat Cell Biol 2008; 10: 53-60.
15. Metzger E, Imhof A, Patel D, et al. Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at histone H3K4. Nature 2010; 464: 792-6.
16. Cheung E, Kraus WL. Genomic analyses of hormone signaling and gene regulation. Annu Rev Physiol 2010; 72: 191-218.
17. Gilmour DS, Lis JT. Detecting protein-DNA interactions in vivo: distribution of RNA polymerase on specific bacterial genes. Proc Natl Acad Sci USA 1984; 81: 4275-9.
18. Solomon MJ, Varshavsky A. Formaldehyde-mediated DNAprotein crosslinking: a probe for in vivo chromatin structures. Proc Natl Acad Sci USA 1985; 82: 6470-4.
19. Wacker DA, Kim TH. From sextant to GPS: twenty-five years of mapping the genome with ChIP. J Cell Biochem 2009; 107: 6-10.
20. Wang Q, Li W, Liu XS, et al. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell 2007; 27: 380-92.
21. Jia L, Berman BP, Jariwala U, et al. Genomic androgen receptoroccupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacity. PLoS One 2008; 3: e3645.
22. Takayama K, Kaneshiro K, Tsutsumi S, et al. Identification of novel androgen response genes in prostate cancer cells by coupling chromatin immunoprecipitation and genomic microarray analysis. Oncogene 2007; 26: 4453-63.
23. Bolton EC, So AY, Chaivorapol C, Haqq CM, Li H, Yamamoto KR. Cell-and gene-specific regulation of primary target genes by the androgen receptor. Genes Dev 2007; 21: 2005-17.
24. Massie CE, Adryan B, Barbosa-Morais NL, et al. New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Rep 2007; 8: 871-8.
25. Wang Q, Li W, Zhang Y, et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 2009; 138: 245-56.
26. Takayama K, Tsutsumi S, Katayama S, et al. Integration of cap analysis of gene expression and chromatin immunoprecipitation analysis on array reveals genome-wide androgen receptor signaling in prostate cancer cells. Oncogene 2011; 30:619-30.
27. Yu J, Yu J, Mani RS, et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 2010; 17: 443-54.
28. Tan PY, Chang CW, Chng KR, Wansa KD, Sung WK, Cheung E. Integration of regulatory networks by NKX3-1 promotes androgendependent prostate cancer survival. Mol Cell Biol 2012; 32: 399-414.
29. Sahu B, Laakso M, Ovaska K, et al. Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO J 2011; 30: 3962-76.
30. Chng KR, Chang CW, Tan SK, et al. A transcriptional repressor co-regulatory network governing androgen response in prostate cancers. EMBO J 2012; 31: 2810-23.
31. Sharma NL, Massie CE, Ramos-Montoya A, et al. The androgen receptor induces a distinct transcriptional program in castrationresistant prostate cancer in man. Cancer Cell 2013; 23: 35-47.
32. Hurtado A, Holmes KA, Ross-Innes CS, Smidt D, Carroll JS. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet 2011; 43: 27-33.
33. Badve S, Turbin D, Thorat MA, et al. FOXA1 expression in breast cancer-correlation with luminal subtype A and survival. Clin Cancer Res 2007; 13: 4415-21.
34. Albergaria A, Paredes J, Sousa B, et al. Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormonereceptor negative tumours. Breast Cancer 2009; 11: R40.
35. Takayama K, Horie-Inoue K, Ikeda K, et al. FOXP1 is an androgen-responsive transcription factor that negatively regulates androgen receptor signaling in prostate cancer cells. Biochem Biophys Res Commun 2008; 374: 388-93.
36. Takayama K, Horie-Inoue K, Suzuki T, et al. TACC2 is an androgen-responsive cell cycle regulator promoting androgen-mediated and castration-resistant growth of prostate cancer. Mol Endocrinol 2012; 26: 748-61.
37. Takayama K, Tsutsumi S, Suzuki T, et al. Amyloid precursor protein is a primary androgen target gene that promotes prostate cancer growth. Cancer Res 2009; 69: 137-42.
38. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18: 11-22.
39. LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci 2007; 8: 499-509.
40. Saitoh T, Sundsmo M, Roch JM, et al. Secreted form of amyloid beta protein precursor is involved in the growth regulation of fibroblasts. Cell 1989; 58: 615-22.
41. Schubert D, Schroeder R, LaCorbiere M, Saitoh T, Cole G. Amyloid beta protein precursor is possibly a heparan sulfate proteoglycan core protein. Science 1988; 241: 223-6.
42. Itoh H, Kataoka H, Koita H, et al. Establishment of a new human cancer cell line secreting protease nexin-II/amyloid beta protein precursor derived from squamous-cell carcinoma of lung. Int J Cancer 1991; 49: 436-43.
43. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644-8.
44. Xu K, Wu ZJ, Groner AC, et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science 2012; 338: 1465-9.
45. Urbanucci A, Sahu B, Seppälä J, et al. Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer. Oncogene 2012; 31: 2153-63.
46. Li G, Fullwood MJ, Xu H, et al. ChIA-PET tool for comp3rehensive chromatin interaction analysis with paired-end tag sequencing. Genome Biol. 2010; 11: R22.
47. Fullwood MJ, Liu MH, Pan YF, et al. An oestrogen-receptoralpha-bound human chromatin interactome. Nature 2009; 462: 58-64.
48. Handoko L, Xu H, Li G, et al. CTCF-mediated functional chromatin interactome in pluripotent cells. Nat Genet 2011; 43: 630-8.
49. Li G, Ruan X, Auerbach RK, et al. Extensive promoter-centered chromatin interactions provide a topological basis for transcription regulation. Cell 2012; 148: 84-98.
50. Shiraki T, Kondo S, Katayama S, et al. Cap analysis gene expression for high-throughput analysis of transcriptional starting point and identification of promoter usage. Proc Natl Acad Sci USA 2003; 100: 15776-81.
51. de Hoon M, Hayashizaki Y. Deep cap analysis gene expression (CAGE): genome-wide identification of promoters, quantification of their expression, and network inference. Biotechniques 2008; 44: 627-32.
52. Katayama S, Tomaru Y, Kasukawa T, et al. RIKEN Genome Exploration Research Group; Genome Science Group (Genome Network Project Core Group); FANTOM Consortium. Antisense transcription in the mammalian transcriptome. Science 2005; 309: 1564-6.
53. Gustincich S, Sandelin A, Plessy C, et al. The complexity of the mammalian transcriptome. J Physiol 2006; 575(Pt 2): 321-32.
54. Carninci P, Kasukawa T, Katayama S, et al. FANTOM Consortium; RIKEN Genome Exploration Research Group and Genome Science Group (Genome Network Project Core Group). The transcriptional landscape of the mammalian genome. Science 2005; 309: 1559-63.
55. Prensner JR, Iyer MK, Balbin OA, et al. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol 2011; 29: 742-9.
56. Maher CA, Kumar-Sinha C, Cao X, et al. Transcriptome sequencing to detect gene fusions in cancer. Nature 2009; 458: 97-101.
57. Rowley JD. Chromosome translocations: dangerous liaisons revisited. Nat Rev Cancer 2001; 1: 245-50.
58. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-6.
59. Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004; 6: 1-6.
60. Murata T, Takayama K, Katayama S, et al. miR-148a is an androgen-responsive microRNA that promotes LNCaP prostate cell growth by repressing its target CAND1 expression. Prostate Cancer Prostatic Dis 2010; 13: 356-61.
61. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature 2012; 489: 57-74.
62. Waltering KK, Helenius MA, Sahu B, et al. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res 2009; 69: 8141-9.